AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Large B-cell Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 420 (planned)
- Started
- Nov 11, 2025
- Main results expected
- Jun 10, 2030
- Fully finished
- Jul 29, 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
SRI - Safety evaluation of R-mini-CHOP × 2 followed by AZD0486: Number of participants with treatment-related adverse events.
Measured over: Up to 1 year
SRI - Tolerability evaluation of R-mini-CHOP × 2 followed by AZD0486: Number of participants with treatment-related adverse events.
Measured over: Up to 1 year
SRI - Determination of the recommended Phase III dose (RP3D)
Measured over: Up to 1 year
Phase 3 - To demonstrate the superiority of R-mini-CHOP x2 followed by AZD0486 compared to R-mini-CHOP x6 regimen.
Measured over: Up to 7 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07215585 · record last updated 2026-10-09 · checked 2026-11-09 15:47 UTC